Supposedly, targeting key enzymes in the serine synthesis pathway (PHGDH, PSAT1, and PSPH) is an effective approach to overcoming resistance to sorafenib in HCC [30]. The gene discussed is PSAT1; the disease is hepatocellular carcinoma.